Evidence map›Paper›PMID 38450504›Full record

ArticleHaematologica2024

Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.

Allison Barraclough, Shivam Agrawal, Dipti Talaulikar, Geoffrey Chong, Edward Yoo, Chan Y Cheah, Nunzio Franco, Bianca Nguyen, Howard Mutsando, Fatima Tahir and 12 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. In pursuit of a functional cure for follicular lymphoma.Hematology. American Society of Hematology. Education Program · 2024
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Allison BarracloughOlivia Newton John Cancer Research and Wellness Centre, Austin Health, Victoria, Australia; Fiona Stanley Hospital, Western Australia.
Shivam AgrawalOlivia Newton John Cancer Research and Wellness Centre, Austin Health, Victoria, Australia; Prince of Wales Hospital, New South Wales.
Dipti TalaulikarCanberra Health Services, Australian Capital Territory, Australia; College of Health and Medicine, Australian National University, Australian Capital Territory.
Geoffrey ChongOlivia Newton John Cancer Research and Wellness Centre, Austin Health, Victoria, Australia; Ballarat Regional Integrated Cancer Centre, Ballarat Health Services, Victoria.
Edward YooFiona Stanley Hospital, Western Australia, Australia; Sir Charles Gairdner Hospital, Western Australia.
Chan Y CheahSir Charles Gairdner Hospital, Western Australia, Australia; Medical School, University of Western Australia, Western Australia.
Nunzio FrancoCanberra Health Services, Australian Capital Territory, Australia; College of Health and Medicine, Australian National University, Australian Capital Territory.
Bianca NguyenFiona Stanley Hospital, Western Australia.
Howard MutsandoToowoomba Hospital, Queensland, Australia; University of Queensland Rural Clinical School, Queensland.
Fatima TahirConcord Repatriation General Hospital, University of Sydney, New South Wales.
Judith TrotmanConcord Repatriation General Hospital, University of Sydney, New South Wales.
Jing HuangSchool of Clinical Sciences at Monash Health, Monash University, Victoria.
Colm KeanePrincess Alexandra Hospital, Queensland.
Mitchel LincolnAlfred Hospital, Victoria.
Tara CochraneGold Coast University Hospital, Queensland, Australia; School of Medicine, Griffith University, Queensland.
Anna M JohnstonRoyal Hobart Hospital, Tasmania.
Michael DickinsonPeter MacCallum Cancer Centre and The Royal Melbourne Hospital, Victoria.
Stephen OpatSchool of Clinical Sciences at Monash Health, Monash University, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Victoria.
Zoe K McQuiltenSchool of Clinical Sciences at Monash Health, Monash University, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Victoria.
Erica M WoodSchool of Clinical Sciences at Monash Health, Monash University, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Victoria.
Gayathri St GeorgeSchool of Public Health and Preventive Medicine, Monash University, Victoria.
Eliza A HawkesOlivia Newton John Cancer Research and Wellness Centre, Austin Health, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Victoria. eliza.hawkes@onjcri.org.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d'Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burden FL patients to harmonize clinical trial populations. The utilization of GELF criteria (GELFc) in routine therapeutic decision- making is poorly described. This multicenter retrospective study evaluated patterns of GELFc at presentation and GELFc utilization in therapeutic decision-making in newly diagnosed, advanced-stage rituximab-era FL. Associations between GELFc, treatment given, and patient survival were analyzed in 300 eligible cases identified between 2002-2019. One hundred and sixty-three (54%) had ≥1 GELFc at diagnosis. The presence or cumulative number of GELFc did not predict progression-free survival in patients undergoing watch-and-wait (W&W) or those receiving systemic treatment. Of interest, in patients with ≥1 GELFc, 16 of 163 (10%) underwent initial W&W (comprising 22% of the W&W cohort). In those receiving systemic therapy +/- radiotherapy, 74 of 215 (34%) met no GELFc. Our data suggest clinicians are using adjunctive measures to make decisions regarding treatment initiation in a significant proportion of patients. By restricting FL clinical trial eligibility only to those meeting GELFc, reported outcomes may not be applicable to a significant proportion of patients treated in routine care settings.

Indexed as

Lymphoma, FollicularAdultAgedAged, 80 and overAustralasiaClinical Decision-MakingFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesRituximabTumor BurdenRituximab

Identifiers

PMID38450504
PMCPMC11443368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.